1.A community-based sero-epidemiological study of hepatitis B infection in Lianyungang, China, 2010
Zhang Ting-lu ; Xiao Zhi-ping ; Ling Hong-yu ; Ge Chang-hong ; Ying Liang ; Ding Qiang ; Xu Kai-ling ; Mao Yan-ming ; Du Yue-he ; Zhu Ling-yang
Western Pacific Surveillance and Response 2012;3(3):69-75
Introduction:The 2010 targets of the China Hepatitis B Prevention Programme were a prevalence of hepatitis B surface antigen (HBsAg) less than 1.0% for children less than five years old and less than 6.0% for the total population. This survey assessed the prevalence of Hepatitis B infection in Lianyungang, Jiangsu province, China in 2009–2010.Methods:Multistage sampling was used with 2372 subjects among 17 selected villages. Blood specimen collection and testing by enzyme-linked immunosorbnet assay (ELISA) were completed using the following markers for hepatitis infection: HBsAg and antibody to HBsAg (anti-HBs); hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe); and hepatitis B core antibody (total anti-HBc). The data were analysed with Epi Info, version 3.3.2.Results:The prevalence of HBsAg was 2.4% (95% Confidence Interval [CI]: 1.8–3.0; Adjusted Prevalence [AP] 2.9%); anti-HBs prevalence was 51.1% (95% CI: 49.1–53.1; AP 49.2%) and total anti-HBc prevalence was 41.7% (95% CI: 39.8–43.7; AP 45.5%). The prevalence of HBsAg and total anti-HBc positivity increased from young to older age groups, yet the prevalence of anti-HBs positivity decreased from young to older age groups (
2.Risk Factors for the Rupture of Bifurcation Intracranial Aneurysms Using CT Angiography.
Guang Xian WANG ; Dong ZHANG ; Zhi Ping WANG ; Liu Qing YANG ; Lei ZHANG ; Li WEN
Yonsei Medical Journal 2016;57(5):1178-1184
PURPOSE: To investigate the clinical and morphological characteristics in relation to risk of bifurcation intracranial aneurysm rupture. MATERIALS AND METHODS: Data from 202 consecutive patients with 219 bifurcation aneurysms (129 ruptured and 90 unruptured) managed at the authors' facility between August 2011 and July 2014 were retrospectively reviewed. Based on their clinical records and CT angiographic findings, the ability of risk factors to predict aneurysm rupture was assessed using statistical methods. RESULTS: Age, hypertension, diabetes mellitus, and cerebral atherosclerosis were negatively correlated with aneurysm rupture. Aneurysms located in the middle cerebral artery, daughter artery ratio, lateral angle ratio (LA ratio), and neck width were negatively correlated with rupture. Aneurysms located in the anterior communicating artery, irregularity, with daughter sac, depth, width, maximum size, aspect ratio (AR), depth-to-width ratio, and bottleneck factor were significantly and positively correlated with rupture. Binary logistic regression model revealed that irregular shape [odds ratio (OR) 6.598] and AR (OR 3.507) strongly increased the risk of bifurcation aneurysm rupture, while age (OR 0.434), cerebral atherosclerosis (OR 0.125), neck width (OR 0.771), and LA ratio (OR 0.267) were negatively correlated with rupture (p<0.05). Receiver operating characteristic analysis revealed the threshold values of AR and LA ratio to be 1.18 and 1.50, respectively. CONCLUSION: Age (≥60 yr), cerebral atherosclerosis, and aneurysms with a larger neck width and larger LA ratio are protective factors against bifurcation aneurysm rupture. An aneurysm with an irregular shape and an increased AR reflect the greater likelihood of a rupture.
Adult
;
Age Factors
;
Aged
;
Aged, 80 and over
;
Aneurysm, Ruptured/*diagnostic imaging
;
Cerebral Angiography/*methods
;
*Computed Tomography Angiography
;
Developmental Disabilities
;
Diabetic Angiopathies/complications
;
Female
;
Humans
;
Hypertension/complications
;
Intracranial Aneurysm/*diagnostic imaging
;
Intracranial Arteriosclerosis/complications
;
Logistic Models
;
Male
;
Middle Aged
;
Middle Cerebral Artery/diagnostic imaging
;
Odds Ratio
;
Protective Factors
;
ROC Curve
;
Retrospective Studies
;
Risk Factors
3.Outcomes of Microendoscopic Discectomy and Percutaneous Transforaminal Endoscopic Discectomy for the Treatment of Lumbar Disc Herniation: A Comparative Retrospective Study.
Arjun SINKEMANI ; Xin HONG ; Zeng Xin GAO ; Su Yang ZHUANG ; Zan Li JIANG ; Shao Dong ZHANG ; Jun Ping BAO ; Lei ZHU ; Pei ZHANG ; Xin Hui XIE ; Feng WANG ; Xiao Tao WU
Asian Spine Journal 2015;9(6):833-840
STUDY DESIGN: Retrospective, case control evaluation of 86 patients who underwent microendoscopic discectomy (MED) and percutaneous transforaminal endoscopic discectomy (PTED) for the treatment of lumbar disc herniation (LDH). PURPOSE: To evaluate the safety and the outcomes of MED and PTED for the treatment of LDH. OVERVIEW OF LITERATURE: MED and PTED are minimally invasive surgical techniques for lower back pain. Studies to date have shown that MED and PTED are safe and effective treatment modalities for LDH. METHODS: A retrospective study was performed in patients with LDH treated with MED (n=50) and transforaminal endoscopic discectomy (PTED; n=36) in our hospital. All patients were followed-up with self-evaluation questionnaires, Oswestry disability index (ODI), medical outcomes study 36-item short form health survey and MacNab criteria. All the patients in both groups were followed up to 12 months after the operation. RESULTS: ODI questionnaire responses were not statistically different between the MED and PTED groups (53.00 vs. 48.72) before treatment. Average scores and minimal disability after 5 days to 12 months of follow-up were 4.96 in the MED group and 3.61 in the PTED group. According to MacNab criteria, 92.0% of the MED group and 94.4% of the PTED group had excellent or good results with no significant difference. CONCLUSIONS: There was no significant difference between MED and PTED outcomes. Further large-scale, randomized studies with long-term follow-up are needed.
Case-Control Studies
;
Diagnostic Self Evaluation
;
Diskectomy*
;
Follow-Up Studies
;
Health Surveys
;
Humans
;
Intervertebral Disc Degeneration
;
Low Back Pain
;
Retrospective Studies*
;
Surgical Procedures, Minimally Invasive
4.Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.
Jia HU ; Li juan CHEN ; Li LIU ; Xiang CHEN ; Ping li CHEN ; Guang YANG ; Wen li HOU ; Ming Hai TANG ; Fan ZHANG ; Xian Huo WANG ; Xia ZHAO ; Yu Quan WEI
Experimental & Molecular Medicine 2008;40(6):617-628
Honokiol is an active compound purified from magnolia that has been shown to induce cell differentiation, apoptosis, and anti-angiogenesis effects, as well as an enhancement in tumor growth delay in combination with chemotherapeutic agents in several mouse xenograft models. Our goal was to investigate the radiosensitization effect of honokiol on lung carcinoma. The radiosensitization effect of liposomal honokiol in Lewis lung carcinoma cells (LL/2) was analyzed using an in vitro clonogenic survival assay. For an in vivo study, Lewis lung carcinoma-bearing C57BL/6 mice were treated with either liposomal honokiol at 25 mg/kg or 5 Gy of single tumor radiation, or a combination of both over 12 days of treatment. The tumor growth delay and the survival time were evaluated. In addition, histological analysis of tumor sections was performed to examine changes by detecting the microvessel density and apoptosis in tumor tissues. In the clonogenic survival assay, LL/2 cells treated with IC50 Lipo-HNK for 24 h showed a radiation enhancement ratio of 1.9. After 12 days of combination treatment, the tumor volume decreased 78% and produced an anti-tumor activity 1.3-fold greater than a predicted additive effect of honokiol and radiation alone. This combination treatment also caused an 8.7 day delay in tumor growth. The cell cycle distribution and histological analysis demonstrated that liposomal honokiol has an anti-tumor effect via inducing apoptosis and inhibiting angiogenesis. Liposomal honokiol can enhance tumor cell radiosensitivity in vitro and in vivo, indicating that radiotherapy combined with liposomal honokiol can lead to greater anti-tumor efficacy.
Angiogenesis Inhibitors/administration & dosage/*therapeutic use
;
Animals
;
Apoptosis
;
Biphenyl Compounds/administration & dosage/*therapeutic use
;
Carcinoma, Lewis Lung/drug therapy/radiotherapy/*therapy
;
Cell Cycle/drug effects/radiation effects
;
Cell Line, Tumor
;
Combined Modality Therapy
;
Humans
;
Lignans/administration & dosage/*therapeutic use
;
Liposomes
;
Lung Neoplasms/drug therapy/radiotherapy/*therapy
;
Magnolia/chemistry
;
Mice
;
Neoplasm Transplantation
;
Neovascularization, Pathologic/drug therapy/radiotherapy
;
Radiation Tolerance
;
Transplantation, Heterologous